229 related articles for article (PubMed ID: 22167585)
21. The tumor promoting roles of erythropoietin/erythropoietin receptor signaling pathway in gastric cancer.
Hu W; Zhang Y; Jiang Z; Wang L; Li J; Chen S; Dai N; Si J
Tumour Biol; 2016 Aug; 37(8):11523-33. PubMed ID: 27086036
[TBL] [Abstract][Full Text] [Related]
22. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
23. Expression pattern of erythropoietin and erythropoietin receptor in experimental model of retinal detachment.
Xie Z; Wu X; Qiu Q; Gong Y; Song Y; Gu Q; Li C
Curr Eye Res; 2007 Sep; 32(9):757-64. PubMed ID: 17882708
[TBL] [Abstract][Full Text] [Related]
24. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
Tanaka T; Nangaku M
Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
[TBL] [Abstract][Full Text] [Related]
25. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
26. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma.
Lee YS; Vortmeyer AO; Lubensky IA; Vogel TW; Ikejiri B; Ferlicot S; Benoît G; Giraud S; Oldfield EH; Linehan WM; Teh BT; Richard S; Zhuang Z
Clin Cancer Res; 2005 Feb; 11(3):1059-64. PubMed ID: 15709172
[TBL] [Abstract][Full Text] [Related]
27. Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to Epo after normal hematopoietic cell transfection with EpoR.
McArthur GA; Longmore GD; Klingler K; Johnson GR
Exp Hematol; 1995 Jul; 23(7):645-54. PubMed ID: 7601257
[TBL] [Abstract][Full Text] [Related]
28. Erythropoietin-dependent autocrine secretion of tumor necrosis factor-alpha in hematopoietic cells modulates proliferation via MAP kinase--ERK-1/2 and does not require tyrosine docking sites in the EPO receptor.
Chen J; Jacobs-Helber SM; Barber DL; Sawyer ST
Exp Cell Res; 2004 Aug; 298(1):155-66. PubMed ID: 15242770
[TBL] [Abstract][Full Text] [Related]
29. Structural and biological properties of erythropoietin in Xenopus laevis.
Nogawa-Kosaka N; Hirose T; Kosaka N; Aizawa Y; Nagasawa K; Uehara N; Miyazaki H; Komatsu N; Kato T
Exp Hematol; 2010 May; 38(5):363-72. PubMed ID: 20193733
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
31. The distinct erythropoietin functions that promote cell survival and proliferation are affected by aluminum exposure through mechanisms involving erythropoietin receptor.
Vittori D; Pregi N; Pérez G; Garbossa G; Nesse A
Biochim Biophys Acta; 2005 Mar; 1743(1-2):29-36. PubMed ID: 15777837
[TBL] [Abstract][Full Text] [Related]
32. Role of a truncated erythropoietin receptor for erythroid differentiation.
Nakamura Y; Tokumoto Y; Nakauchi H
Biochem Biophys Res Commun; 1996 Jan; 218(1):205-9. PubMed ID: 8573132
[TBL] [Abstract][Full Text] [Related]
33. Human, rat, and mouse kidney cells express functional erythropoietin receptors.
Westenfelder C; Biddle DL; Baranowski RL
Kidney Int; 1999 Mar; 55(3):808-20. PubMed ID: 10027918
[TBL] [Abstract][Full Text] [Related]
34. [Proliferative signal transmission mediated by EpoR in leukemic cell lines].
Fan H; Kanji S; Zhai M
Zhonghua Xue Ye Xue Za Zhi; 2000 Jun; 21(6):294-7. PubMed ID: 11876995
[TBL] [Abstract][Full Text] [Related]
35. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Lai SY; Childs EE; Xi S; Coppelli FM; Gooding WE; Wells A; Ferris RL; Grandis JR
Oncogene; 2005 Jun; 24(27):4442-9. PubMed ID: 15856028
[TBL] [Abstract][Full Text] [Related]
36. Expression of erythropoietin and angiogenic growth factors following inner ear injury of newborn rats.
Gross J; Moller R; Amarjargal N; Machulik A; Fuchs J; Ungethüm U; Kuban RJ; Henke W; Haupt H; Mazurek B
Prague Med Rep; 2009; 110(4):310-31. PubMed ID: 20059883
[TBL] [Abstract][Full Text] [Related]
37. Location and the functionality of erythropoietin receptor(s) in A2780 cells.
Solár P; Hrčková G; Varinská L; Solárová Z; Kriška J; Uhrínová I; Kello M; Mojžiš J; Fedoročko P; Sytkowski AJ
Oncol Rep; 2012 Jul; 28(1):141-6. PubMed ID: 22552716
[TBL] [Abstract][Full Text] [Related]
38. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells.
Wu P; Zhang N; Wang X; Zhang C; Li T; Ning X; Gong K
PLoS One; 2012; 7(9):e45122. PubMed ID: 23028796
[TBL] [Abstract][Full Text] [Related]
39. Effect of erythropoietin on Leydig cell is associated with the activation of Stat5 pathway.
Yamazaki T; Kanzaki M; Kamidono S; Fujisawa M
Mol Cell Endocrinol; 2004 Jan; 213(2):193-8. PubMed ID: 15062567
[TBL] [Abstract][Full Text] [Related]
40. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
